Teresa Boitano, M.D., is a fellow in the Department of Obstetrics and Gynecology’s Division of Gynecologic Oncology. Her team was recently awarded a National Ovarian Cancer Coalition Quality of Life Research pilot grant.
Chemobrain and chemofog are common side effects of chemotherapy that affect cognitive function, including memory, attention, and processing speed. These side effects can be particularly distressing for gynecological cancer patients, who may already be dealing with physical and emotional challenges related to their diagnosis and treatment.
Up to 75% of gynecologic oncology patients will have chemobrain associated with their chemotherapy treatment. However, there is limited research in this patient population as to what the best possible treatments for chemobrain are. Boitano is working with a multidisciplinary team which will allow for patients to receive the best evaluation and treatment possible.
Boitano's pilot study will focus on developing and testing a cognitive rehabilitation program in conjunction with the neuropsychology cancer team that is tailored to the unique needs of gynecological cancer patients. The program will include a smartphone/tablet application that patients will use and undergo cognitive training interventions in the form of problem-solving games.
The National Ovarian Cancer Coalition Quality of Life Research Grant pilot grant is a highly competitive award, and Boitano's selection is a testament to the importance of her research. This grant will provide critical funding for her pilot study and could pave the way for larger studies in the future.
“My team and I are extremely grateful for this grant and the opportunity to perform this research in order to help improve the quality of life in our chemotherapy patients,” said Boitano.
Boitano's research has the potential to make a significant impact on the lives of gynecological cancer patients. By developing a cognitive rehabilitation program that is tailored to the unique needs of this population, she could help improve the quality of life for countless individuals who have been affected by this disease.
By using a novel mobile cognitive training application, this study will evaluate a specific treatment option that if shown to be beneficial, will be easily accessible to all gynecologic oncology patients undergoing chemotherapy treatment.
The UAB community is proud to have Boitano as a fellow in the UAB Department of OB/GYN and congratulates her on this well-deserved recognition. Her work represents an important step forward in the field of gynecological oncology and serves as a reminder of the vital role that research plays in improving the lives of cancer patients.